Security National Bank Invests $125,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Security National Bank purchased a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 299 shares of the pharmaceutical company’s stock, valued at approximately $125,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Sherbrooke Park Advisers LLC lifted its stake in shares of Vertex Pharmaceuticals by 65.3% during the third quarter. Sherbrooke Park Advisers LLC now owns 2,645 shares of the pharmaceutical company’s stock valued at $920,000 after acquiring an additional 1,045 shares during the period. Telos Capital Management Inc. grew its position in shares of Vertex Pharmaceuticals by 1.6% during the 4th quarter. Telos Capital Management Inc. now owns 15,073 shares of the pharmaceutical company’s stock worth $6,133,000 after buying an additional 237 shares during the period. Morgan Stanley raised its stake in shares of Vertex Pharmaceuticals by 3.2% during the third quarter. Morgan Stanley now owns 2,870,101 shares of the pharmaceutical company’s stock worth $998,050,000 after buying an additional 89,217 shares during the last quarter. ARK Investment Management LLC lifted its holdings in Vertex Pharmaceuticals by 7.7% in the fourth quarter. ARK Investment Management LLC now owns 124,197 shares of the pharmaceutical company’s stock valued at $50,535,000 after buying an additional 8,866 shares during the period. Finally, Brevan Howard Capital Management LP boosted its stake in Vertex Pharmaceuticals by 216.3% in the fourth quarter. Brevan Howard Capital Management LP now owns 4,830 shares of the pharmaceutical company’s stock valued at $1,965,000 after acquiring an additional 3,303 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Activity at Vertex Pharmaceuticals

In related news, EVP Edward Morrow Atkinson III sold 7,288 shares of the firm’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $478.00, for a total value of $3,483,664.00. Following the completion of the transaction, the executive vice president now directly owns 15,972 shares of the company’s stock, valued at $7,634,616. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, CEO Reshma Kewalramani sold 1,565 shares of the firm’s stock in a transaction that occurred on Friday, May 24th. The stock was sold at an average price of $457.00, for a total value of $715,205.00. Following the completion of the sale, the chief executive officer now directly owns 121,374 shares of the company’s stock, valued at $55,467,918. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Edward Morrow Atkinson III sold 7,288 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $478.00, for a total value of $3,483,664.00. Following the transaction, the executive vice president now directly owns 15,972 shares in the company, valued at $7,634,616. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 26,086 shares of company stock valued at $11,983,266. 0.20% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have commented on VRTX shares. Guggenheim upped their target price on shares of Vertex Pharmaceuticals from $445.00 to $450.00 and gave the company a “buy” rating in a research report on Thursday, April 18th. UBS Group cut their target price on Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating on the stock in a research note on Wednesday, April 17th. Piper Sandler boosted their target price on Vertex Pharmaceuticals from $450.00 to $456.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 7th. Argus increased their price target on shares of Vertex Pharmaceuticals from $465.00 to $550.00 and gave the company a “buy” rating in a research report on Monday, June 17th. Finally, Needham & Company LLC restated a “hold” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 7th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $444.23.

Vertex Pharmaceuticals Stock Up 0.0 %

Shares of VRTX traded up $0.18 during mid-day trading on Wednesday, hitting $474.00. 538,496 shares of the company’s stock were exchanged, compared to its average volume of 1,223,748. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.50 and a quick ratio of 3.29. Vertex Pharmaceuticals Incorporated has a 52 week low of $335.82 and a 52 week high of $486.42. The company has a market cap of $122.32 billion, a PE ratio of 30.79, a P/E/G ratio of 2.43 and a beta of 0.41. The company has a 50-day simple moving average of $440.20 and a 200 day simple moving average of $424.71.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share for the quarter, beating analysts’ consensus estimates of $3.66 by $1.10. Vertex Pharmaceuticals had a net margin of 39.46% and a return on equity of 23.08%. The business had revenue of $2.69 billion during the quarter, compared to the consensus estimate of $2.58 billion. During the same quarter last year, the firm earned $2.67 earnings per share. The firm’s revenue for the quarter was up 13.3% compared to the same quarter last year. On average, research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.22 earnings per share for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.